Orally administered treatment for age-related macular degeneration Macular degeneration is a major cause of blindness in the elderly → High unmet medical needs due to the limitations of existing treatments
 |
Age-Related Macular Degeneration |
 |
|
 |
Age-related macular degeneration is an ocular disease that causes visual impairment due to aging and changes to the macula lutea, which is located in the center of the inner retina. |
|
Age-related macular degeneration is a major cause of blindness in people over 60 |
|
Wet and dry macular degeneration |
Existing medicine and unmet medical needs
Global market perspective
Orally administered treatment for age-related macular degeneration Phase 2a clinical trial study design
Study overview
Design: Multi-center, randomized, double-blind, placebo-control
ObjectivesTo evaluate tolerability, safety and efficacy arm
Number of subjects3groups(treatment arm I, II and placebo arm)
Study schedule
| 2019.08 | : | IND submitted (Ministry of Food and Drug Safety)  |
| 2019.12.04 | : | IND approved (Ministry of Food and Drug Safety) |
| 2020.01 | : | IRB approval for Samsung Medical Center and 7 other sites |
| 2020.03 | : | Administered to the first patient |
Orally administered treatment for age-related macular degeneration
